Company Description
Aktis Oncology, Inc. operates as a clinical-stage oncology company that engages in the development of targeted radiopharmaceutical therapies for cancer treatment.
The company offers a miniprotein radioconjugate platform to discover and develop radiopharmaceutical therapies that deliver the tumor-killing properties of radioisotopes.
It offers Nectin-4, a miniprotein radioconjugate for the treatment of locally advanced or metastatic urothelial cancer.
Its products include AKY-1189 to deliver a radioisotope to Nectin-4 expressing tumors for the treatment of metastatic urothelial cancer, breast cancer, NSCLC, colorectal cancer and cervical cancer; and AKY-2519 to deliver radioisotope to B7-H3 CD276 expressing tumors targeting prostate, lung and other solid tumors.
The company was formerly known as HotKnot Therapeutics, Inc. and changed its name to Aktis Oncology, Inc. in April 2020.
Aktis Oncology, Inc. was incorporated in 2020 and is based in Boston, Massachusetts.
| Country | United States |
| Founded | 2020 |
| IPO Date | Jan 9, 2026 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 76 |
| CEO | Matthew Roden |
Contact Details
Address: 17 Drydock Avenue, Suite 17-401 Boston, Massachusetts 02210 United States | |
| Phone | 617-461-4023 |
| Website | aktisoncology.com |
Stock Details
| Ticker Symbol | AKTS |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $18.00 |
| CIK Code | 0002035832 |
| CUSIP Number | 01021M104 |
| ISIN Number | US01021M1045 |
| Employer ID | 85-2584233 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Matthew Roden, PhD | President, Chief Executive Officer and Director |
| Kyle D. Kuvalanka | Chief Financial Officer |
| Shulamit Ron-Bigger, PhD | Chief Operating Officer |
| Paul L. Feldman, PhD | Chief Scientific Officer |
| Todd Foley, MBA | Chair of the Board of Directors |
| Ken Herrmann, MD | Director |
| Helen S. Kim, MBA | Director |
| Andrew Levin, MD, PhD | Director |
| Oleg Nodelman | Director |
| Lloyd M. Segal, MBA | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 20, 2026 | SCHEDULE 13D | Filing |
| Jan 20, 2026 | SCHEDULE 13D | Filing |
| Jan 15, 2026 | SCHEDULE 13D | Filing |
| Jan 14, 2026 | SCHEDULE 13D | Filing |
| Jan 12, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Jan 12, 2026 | 8-K | Current Report |
| Jan 9, 2026 | 424B4 | Prospectus |
| Jan 8, 2026 | EFFECT | Notice of Effectiveness |
| Jan 8, 2026 | CERT | Certification by an exchange approving securities for listing |
| Jan 7, 2026 | 8-A12B | Registration of securities |